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WHAT THIS PAPER ADDS
 In the existing literature, it remains controversial which upper arm arteriovenous ﬁstula (AVF) has the best performance, and the
number of comparative studies is limited. Our results provide nformation to make a decision in clinical practice.a r t i c l e i n f o
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Objective: To compare the brachiocephalic (BC) and basilic vein transposition (BVT) arteriovenous ﬁstula
(AVF) with regard to maturation, patency, blood ﬂow and complication rates.
Design: A retrospective chart review.
Materials and method: Between January 2000 and December 2010, consecutive patients undergoing BC or
BVT AVF were included. Patient characteristics were collected retrospectively from digital patient ﬁles
and a prospective database of haemodialysis patients.
Results: A total of 173 autologous upper arm AVFs (87 BC and 86 BVT) were created in 151 patients. Mean
(SEM) follow-up was 19  1.4 months (range 0e100). There were no differences between the groups in
respect to brachial artery and cubital fossa vein diameters, time to ﬁrst use, ﬂow and the number of
secondary interventions.
Operative time was signiﬁcantly longer (P < 0.001) and the mid upper arm vein diameter before
bifurcation greater (P ¼ 0.038) in BVT patients. The 1- and 2-year primary patency rates for the whole
cohort was 40.8% and 30.2% with secondary patency rates of 78.0% and 72.4%. There was no difference
between the groups for these outcomes (P ¼ 0.951, P ¼ 0.516, respectively).
Conclusion: With the exception of the efferent vein diameter in the mid upper arm and operative time,
there was no difference between a BC and BVT AVF.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The National Kidney Foundation Dialysis Outcome and Quality
Initiative (NKF-DOQI) and the European Best Practice Guidelines on
Vascular Access recommend the use of an autologous upper
extremity arteriovenous ﬁstula (AVF) instead of a prosthetic arte-
riovenous graft, and this should be constructed as distal as possi-
ble.13 Due to a small diameter of either the radial artery or the
cephalic vein, not all patients are candidates for a radiocephalic
AVF. In these patients, the DOQI guidelines recommend. Fioole).
ciety for Vascular Surgery. Publishea brachiocephalic (BC) AVF. If the cephalic vein in the upper arm is
not available, a basilic vein transposition (BVT) or an arteriovenous
prosthetic graft should be attempted. However, prosthetic arte-
riovenous grafts are associated with decreased patency rates and
higher complication rates in addition to higher yearly costs
compared to autologous AVFs.46 For this reason, many centres aim
at a high BVT AVF use in patients without other autologous AVF
options in the arm.
In contrast to the cephalic vein, the basilic vein runs deep on the
medial side of the upper arm. The vein has to be transposed to
a superﬁcial and lateral position to be accessible for cannulation.
Therefore, constructing a BVT AVF is a more complex procedured by Elsevier Ltd. All rights reserved.
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some advantages over the cephalic vein. It is a large vein which is
available and suitable in almost every patient. The number of
comparative studies is limited and it is therefore unclear which
upper arm AVF performs best.7,8 The aim of this study was to
compare the BC and BVT AVF in our institution with regard to
maturation, patency, ﬂow and complication rates.
Patients and Methods
Between January 2000 and December 2010, all consecutive
patients who underwent construction of a BC9 or BVT10 AVF were
included. Patient characteristics were collected retrospectively
from digital patient ﬁles and a prospectively recorded database on
haemodialysis patients (Diamant, Diasoft B.V. Leusden, The
Netherlands). The database contains data on age, gender, co-
morbidity, primary kidney disease, ﬁstula history, preoperative
and postoperative duplex data, type of surgery, date of ﬁrst use,
ﬂow measurements, complications and secondary interventions.
Preoperative assessment
Preoperative work-up included physical examination and
duplex ultrasound (DUS). Arterial patency was assessed by arterial
pulse examination and performance of the Allen test. Venous
evaluation consisted of examination of the veins of the upper arm,
cubital fossa and lower arm with a tourniquet in place. Preferably
the non-dominant arm was evaluated with DUS. The diameter and
peak systolic velocity (PSV) of the radial, ulnar and brachial artery
weremeasured. The vein diameter and depth of the vein in the arm
were assessed. In our series, patients with central venous stenosis
would be excluded for an ipsilateral upper arm ﬁstula. Either this
stenosis would be treated by angioplasty or an AVF would be
constructed on the contralateral arm. Patients were eligible for
surgery if both the artery and vein contained no stenosis and the
diameter was larger than 2 mm. This protocol has been published
previously.11 If the cephalic veinwas not suitable for a radiocephalic
or BC AVF, a BVT AVF was performed.
Surgical procedure
Five surgeons performed both operations with standardised
technique. The preferred type of anaesthesia was locoregional.
General anaesthesia was performed if locoregional anaesthesia was
not sufﬁcient or on the patients’ request. The BC AVF is created
following a transverse incision in the cubital fossa. The brachial
artery and cephalic vein are identiﬁed. After an arteriotomy of
7 mm, an end-to-side anastomosis is made. Creating a BVT AVF
requires complete mobilisation of the basilic vein in the upper arm.
In addition to the transverse incision in cubital fossa, two longitu-
dinal incisions are made in line over the basilic vein. The brachial
fascia is opened and the basilic vein is identiﬁed. After mobilisation,
the basilic vein is tunnelled subcutaneously anterior to the biceps
brachii muscle. In the cubital fossa an end-to-side anastomosis is
made after an arteriotomy of 7 mm.
Surveillance
Four weeks after surgery, DUS was performed. If an early
stenosis was assessed, patients were scheduled for percutaneous
transluminal angioplasty (PTA) to improve maturation. A signiﬁ-
cant stenosis was deﬁned as a PSV of more than 400 cm s1 on DUS
or a luminal diameter reduction of 50% on angiography.12,13 When
ﬂow decline was measured during dialysis, patients were referred
for DUS and in case of a stenosis, a PTAwas performed. If a stenosiscould not be treated endovascularly, a surgical intervention was
performed. This protocol has been published previously.11
Deﬁnitions
Patency rates were deﬁned and calculated in accordance with
reported standards as described by Sidawy.14 Fistula failure was
deﬁned as any event that required an intervention tomaintain or re-
establish patency, including stenosis, thrombosis, pseudo-aneurysm,
infection, haemorrhage, ischaemia of the hand and patient dissatis-
faction leading to another type of access. Flow was deﬁned as the
mean ﬂow measured in the ﬁrst 4 months after starting dialysis. In
AVFs that were not cannulated prior to a secondary intervention,
blood ﬂow was measured after the intervention.
Statistics
Measured values are reported as mean  standard error of the
mean (SEM). Differences between groups were investigated using
the Student t-test. The c2 test was used for categorical variables.
Correlations were assessed using Pearson’s correlation. Patency
rates were estimated using KaplaneMeier curve. Patency rates
were based on a per ﬁstula analysis. Comparison between survival
curves wasmade by the log-rank test. A statistical software package
(Statistical Package for the Social Sciences (SPSS) version 15.0,
Chicago, IL, USA) was used for statistical analysis, where P  0.05
was considered statistically signiﬁcant.
Results
Demographics
A total of 173 autologous upper arm AVFs (out of a total of >900
AVFs in the same time period) were created in 151 patients, of
which 87 were BC and 86 BVT AVFs. The mean age was 62.6  1.07
years. A small majority of the patients was male (52%). The BVT AVF
was constructed signiﬁcantly more frequent among females. The
mean body mass index (BMI) was 26.0  0.8 and was not signiﬁ-
cantly different between the patients in the BC and BVT group
(Table 1). In the BC AVF group, 19 patients have had one previous
ﬁstula and one patient had two previous ﬁstulae in the ipsilateral
arm. In the BVT AVF group, 27 patients have had one previous
ﬁstula and nine patients had two previous ﬁstulae in the ipsilateral
arm. Signiﬁcantly, more patients had previous ﬁstulae in the BVT
AVF group (P ¼ 0.006).
Artery and vein diameters
The preoperative mean diameter of the brachial artery in the
cubital fossa was not signiﬁcantly different between BC and BVT
AVF (4.2  1.4 mm and 4.1  1.3 mm, respectively, P ¼ 0.550). In
patients with a BC AVF, the mean preoperative diameter of the
cephalic vein in the cubital fossa was 3.5  1.4 mm and for patients
with a BVT AVF, the preoperative diameter of the basilic vein was
3.3 1.8 mm (P¼ 0.509). In the mid upper arm, the mean diameter
of the efferent vein, proximal to the conﬂuence with the median
cubital vein, was signiﬁcantly different in the BC and the BVT AVF
group (3.3  1.5 mm vs. 3.8  1.8 mm, respectively, P ¼ 0.038)
(Table 2).
Operation time
The operation time was signiﬁcantly shorter in patients who
received a BC AVF compared to patients with a BVT AVF
(77  2.4 min and 133  2.9, respectively, P < 0.001) (Table 2).
Table 3
Reason for ﬁrst intervention.
BC AVF
Nr. of
patients (%)
BVT AVF
Nr. of patients
(%)
P-value Mean time
to intervention
in days (SEM)
Stenosis 27 (31) 33 (38) 0.286 289 (36)
Thrombosis 9 (10) 16 (19) 0.115 201 (76)
Steal 10 (11) 2 (2) 0.019 166 (38)
Bleeding 3 (3) 5 (6) 0.494 304 (149)
Pseudo aneurysm 3 (3) 1 (1) 0.621 364 (180)
Unknown 1 (1) 0 0.497 e
Total 53 (61) 57 (66) 245 (29)
BC AVF: Brachiocephalic arteriovenous ﬁstula, BVT AVF: Basilic vein transposition
arteriovenous ﬁstula.
Table 1
Patient characteristics.
BC AVF
n ¼ 87
BVT AVF
n ¼ 86
P-value
Sex 0.018
Male 53 (61%) 37 (43%)
Female 34 (39%) 49 (57%)
Mean age (years) 64.1 61.1 0.155
BMI 26.5 25.4 0.491
Male 27.6 26.8
Female 25.0 24.3
Co-morbidity
Hypertension 71 (82) 66 (77) 0.431
Cardiac disease 51 (59) 48 (56) 0.709
Hyperlipidaemia 51 (59) 41 (48) 0.149
Diabetes mellitus 38 (44) 42 (49) 0.496
Pulmonary disease 21 (24) 17 (20) 0.488
Carotid disease 5 (6) 1 (1) 0.099
Primary renal disease 0.826
Hypertensive nephropathy 29 29
Diabetic nephropathy 26 23
Glomerulonephritis 9 12
Polycystic kidney disease 2 4
Othera 21 18
Previous vascular access in ipsilateral arm 20 36 0.006
BMI: Body mass index; BC AVF: Brachiocephalic arteriovenous ﬁstula; BVT AVF:
Basilic vein transposition arteriovenous ﬁstula.
a Other: Atherosclerosis, cardial, laxatives abuses, drugs abuses, eci, M. Kahler,
postrenal obstruction, relapsing urinary tract infection, SLE.
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Two patients were considered early technical failures, in which
both were bleeding of the ﬁstula. A total of 12 ﬁstulae did not
mature (7%) and were considered early failures. Of these, seven
were BC and ﬁve were BVT AVFs. In these ﬁstulae, non-maturation
was the result of stenosis or thrombosis.
Twenty-three ﬁstulae matured, but were not used. In total, 138
ﬁstulae were eventually used for dialysis, of which 70 were BC and
68 BVTAVFs. Themean time between surgery and ﬁrst use for all BC
and BVT AVFs was 12  1.8 weeks and 12  2.2 weeks, respectively
(P ¼ 0.948). For BC and BVT AVFs that were used in the ﬁrst 6
months, this was 7  0.5 weeks and 8  0.5 weeks, respectively
(P ¼ 0.550).
The mean ﬂow in the ﬁrst 4 months after cannulation of the BC
and BVT AVF was 1205  91 ml min1 and 1276  101 ml min1,
respectively (P ¼ 0.603). In BC AVFs, no correlation between ﬂow
and preoperative diameters of the cephalic vein measured in the
cubital fossa and at themid upper armwas observed (P¼ 0.694 and
P ¼ 0.271, respectively). Also, in BVT AVFs, no correlation was
observed between ﬂow and the diameters of the basilica vein
measured in the antecubital fossa and at the mid upper arm
(P ¼ 0.906 and P ¼ 0.775, respectively).Table 2
Characteristics of the upper arm arteriovenous ﬁstulas.
BC AVF mean
 SEM
BVT AVF mean
 SEM
P-value
Diameters (millimetre)
Art. Brachialis in the antecubital fossa 4.2  1.4 4.1  1.3 0.550
Efferent vein in cubital fossa 3.5  1.4 3.3  1.8 0.509
Efferent vein in the mid upper arm 3.3  1.5 3.8  1.8 0.038
Surgery Time (minutes) 77  2.4 133  2.9 <0.001
Time to ﬁrst use all ﬁstulas (weeks) 12  1.8 12  2.2 0.948
Fistulas used in the ﬁrst 6 months 7  0.5 8  0.5 0.550
Flow (milliliter/minute) 1205  91 1276  101 0.603
Subsequent Interventions (number) 1.24  0.23 0.93  0.13 0.237
BC AVF: Brachiocephalic arteriovenous ﬁstula; BVT AVF: Basilic vein transposition
arteriovenous ﬁstula.Fistula failure and secondary interventions
Fistula failure occurred in 110 (64%) AVFs (Table 3). In these
ﬁstulae, 88 secondary interventions were performed of which 58
were endovascular. Fifty-seven ﬁstulae developed a second failure
and 46 of these ﬁstulae underwent an intervention, of which 36
were endovascular. A total of 12 patients developed steal. Four
patients had mild symptoms and could be treated conservatively.
Seven patients were treated by banding or revision using distal
inﬂow. One ﬁstula was ligated. More BC AVFs developed steal
compared to BVT AVF (P ¼ 0.019). There was no difference between
the number of interventions performed in BC and BVT AVFs
(P ¼ 0.237).
Patency
Mean follow-up of all 173 ﬁstulae was 19  1.4 months (range
0e100). In total, 55 patients died during follow-up. The 1- and
2-year primary patency rates of all AVFs were 40.8% and 30.2%,
respectively (Table 4, Fig. 1). No signiﬁcant difference between the
different types of AVFs was observed (log-rank, P ¼ 0.951). The
overall primary assisted patency rates were 73.4% at 1 year and
66.8% at 2 years. The overall secondary patency rates were 78.0% at
1 year and 72.4% at 2 years. Again, no signiﬁcant differences
between the different types of AVFs were observed for primary
assisted and secondary patency rates (log-rank, P ¼ 0.628 and
P ¼ 0.516, respectively).
Discussion
In our series of 173 autologous upper arm AVFs, no difference in
ﬂow dynamics, maturation, patency and complication rates was
observed between BC and BVT AVFs. The only differences were the
operation time, the number of patients with previous ﬁstulae andTable 4
Patency rates by ﬁstula type.
All patients
n ¼ 173
BC AVF
n ¼ 87
BVT AVF
n ¼ 86
P-value
Primary patency (%) 0.951
1-year 40.8 40.0 41.3
2-year 30.2 32.6 27.2
Primary assisted patency (%) 0.628
1-year 73.4 78.4 68.5
2-year 66.8 69.2 64.3
Secondary patency (%) 0.516
1-year 78.0 83.1 73.1
2-year 72.4 76.0 68.9
BC AVF: Brachiocephalic arteriovenous ﬁstula; BVT AVF: Basilic vein transposition
arteriovenous ﬁstula.
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Figure 1. Kaplan-Meyer curve of the primary, primary assisted and secondary patency of both BC and BVT AVF.
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which were signiﬁcantly higher in the BVT AVF group.
When constructing a radiocephalic AVF is not possible or has
failed, other options are usually possible such as a more proximal
radiocephalic AVF, an ulnar AVF or various transposition or looped
forearm AVFs. In case there are no possibilities in the forearm, two
alternative efferent veins in the upper arm are available. In our
institution, less and less looped forearm AVFs are performed. This
might contribute to a high number of BVT AVFs. The European and
North-American guidelines recommend the construction of a BC
AVF prior to a BVT AVF.1,2 Nonetheless, some clinicians may prefer
the basilic vein for its larger diameter and the fact that the vein runs
deep and is thus protected from damage caused by previous ven-
apuncture.8,15,16 Several studies have reported on the results of the
BVT, with a 1- and 2-year primary patency rate of 72% (35e92) and
60.4% (28e86), respectively.16 The primary patency rate of BC
AVF in the literature varies. A study from the Netherlands reported
a 1- and 2-year primary patency rate of 55% and 40%, respectively,
and a secondary patency rate of 79% and 68%.17 Woo et al.
reported a 1- and 2-year primary patency rate of 56% and51%, and
a 1- and 2-year secondary patency of 66% and 59%, respectively.15
The 1- and 2-year secondary patency rates of the BC and BVT AVF in
our series were similar to the results reported in other pub-
lications.1820 The disappointing primary patency rate in our series
may be explained by the intensive surveillance strategy and high
early secondary intervention rate in our hospital to facilitate
maturation. Comparative studies were done between BC AVF and
BVT AVF and, as in our series, they did not ﬁnd differences between
patency rates.8,21
Some studies imply that the BVT AVF is more prone to develop
steal syndrome and forearm oedema.1,21,22 The prevalence of steal is
described around 5e15% and oedema around 21e24%.2224 In
a more recent study, however, the frequency of steal and oedema
was 4% and 4%, respectively.21 Koksoy et al. even reported that there
was no clinically signiﬁcant steal syndrome in their study.8 Ascher
et al. reported steal to bemore prevalent with BVTAVF compared to
BC AVF and that this was probably caused by the larger diameter of
the basilica vein.25 In our series, more ﬁstulae were complicated by
steal in the BC AVF group than in the BVT AVF group. Despite the
greater basilic vein diameter, steal was more common in the BC
group.
In selected patients, the BVT AVF may perform better than a BC
AVF. Gonzalez et al. demonstrated in a safety-net population (i.e.,
older patients, women, African Americans, diabetes, peripheral
vascular disease or previous access failure) that in a two-stage BVT
AVF primary patency is marginally improved (P ¼ 0.08) compared
to other AVF.26 Furthermore, in a study with 2422 patients, it wasdemonstrated that if the BVT AVF only is performed as a third
choice for vascular access it has superior primary patency rates
compared to that of a BC AVF.27
In our series, more females were present in the BVT AVF group
compared to BC AVF. Stoikes et al. described a series in which
superﬁcialisation of the efferent vein was performed more often in
obese patients compared to non-obese patients. The majority of
these patients were female.28 We did not observe a difference in
BMI between males or females. However, the body fat in men is
differently distributed compared to women and it may be that
more pronounced subcutaneous fat in the arms of women inﬂu-
enced the selection of the AV ﬁstula. However, other studies
demonstrated that obesity did not inﬂuence maturation, AVF
revision or patency.29,30 In obese patients, AVF cannulation might
be difﬁcult. In these patients, a BVT AVF has the advantage of
tunnelling the basilic vein superﬁcially in the subcutis.
The most important limitation of this study is the retrospective
data collection and the non-randomised comparison. Conse-
quently, the results are subject to selection bias. Nevertheless, with
the exception of sex, all patient characteristics are comparable for
both groups.
In conclusion, with the exception of surgery time andmid upper
arm vein diameters, we found no differences between the BC and
BVT AVF, although more females had a BVT AVF compared to men
and more patients with BVT AV ﬁstulae had more previous ﬁstulae.
Since the construction of a BC AVF requires a smaller operation, this
should be the preferred upper arm AVF when both the cephalic and
basilica vein are available.
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